Lhasa Limited release new data to AI/PDE project users

New PDE data is released into the AI/PDE database.

23 September 2021

Lhasa Limited releases new data to it's Nitrites in Excipients project users

04 June 2021

Lhasa Limited releases new data into its Intermediates Database

25 May 2021

20 tips for nitrosamine impurity assessment

Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!

05 August 2021

The top 5 benefits of data sharing with Vitic [an infographic]

08 April 2021

Working together to address the potential presence of nitrosamine impurities in medications

25 January 2021

Lhasa Limited release new data to AI/PDE project users

New PDE data is released into the AI/PDE database.

23 September 2021

How to make mutagenicity assessment a simpler task

A key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.

Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!

15 September 2021

Lhasa Limited release new data to AI/PDE project users

New PDE data is released into the AI/PDE database.

23 September 2021

Lhasa Limited releases Nexus 2.4 with enhanced ICH M7 expert review support

22 July 2021

Lhasa Limited releases new data to it's Nitrites in Excipients project users

04 June 2021

How to make mutagenicity assessment a simpler task

A key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.

Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!

15 September 2021

Shaping Lhasa Limited’s scientific direction through collaboration

09 September 2021

A day in the life of a Marketing Executive at Lhasa Limited

23 August 2021